Evidence map›Paper›PMID 35153292›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2022

Novel Insights into the Stemness and Immune Privilege of Mesenchymal Stem Cells from Human Wharton Jelly by Single-Cell RNA Sequencing.

Zikuan Leng, Longyu Li, Xiang Zhou, Guangyao Dong, Songfeng Chen, Guowei Shang, Hongwei Kou, Bo Yang, Hongjian Liu

Open access · greenAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Zikuan LengDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Longyu LiDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Xiang ZhouDepartment of Orthopedics, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China (mainland).
Guangyao DongDepartment of Obstetrics, Kaifeng Maternal and Child Health Hospital, Kaifeng, Henan, China (mainland).
Songfeng ChenDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Guowei ShangDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Hongwei KouDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Bo YangDepartment of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Hongjian LiuDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
First Affiliated Hospital of Zhengzhou University · CNKaifeng City Children's Hospital · CNThird Affiliated Hospital of Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Fundamental and clinical interest in mesenchymal stem cells (MSCs) has risen dramatically over the past 3 decades. The immunomodulatory and differentiation abilities are the main mechanisms in vitro and in vivo. However, increasing evidence casts doubt on the stemness and immunogenicity of MSCs. MATERIAL AND METHODS We conducted a high-throughput 10x RNA sequencing and Smart-seq2 scRNA-seq analysis to reveal gene expression of Wharton jelly MSCs (WJ-MSCs) at a single-cell level. Multipotent differentiation, subpopulations, marker genes, human leucocyte antigen (HLA) gene expression, and cell cluster trajectory analysis were evaluated. RESULTS The WJ-MSCs had considerable heterogeneity between cells in terms of gene expression. They highly, partially, and hardly expressed genes related to mesodermal differentiation, endodermal differentiation, and ectodermal differentiation, respectively. Some cells seem to be bipotent or unipotent stem cells. Further, Monocle and cell cluster trajectory analysis demonstrated that 1 of the 3 divided clusters performed as stem cells, accounting for 12.6% of the population. The marker genes for a stem cell cluster were CRIM1, GLS, PLOD2, NEXN, ACTR2, FN1, MBNL1, LMOD1, COL3A1, NCL, SEC62, EPRS, COL5A2, COL8A1, and VCAN. In addition, the MSCs also highly, partially, and hardly expressed HLA-I antigen genes, HLA-II genes, and the HLA-G gene, respectively, indicating that MSCs probably have immunogenicity. A Kyoto Encyclopedia of Genes and Genomes pathway analysis of the 3 clusters demonstrated that they were mainly connected with viral infectious diseases, cancer, and endocrine and metabolic disorders. The most expressed transcription factors were zf-C2H2, HMG/HMGY, and Homeobox. CONCLUSIONS We found that only a subpopulation of WJ-MSCs are real stem cells and WJ-MSCs probably do not have immune privilege.

Indexed as

Immune PrivilegeCell DifferentiationCell ProliferationCells, CulturedHumansMesenchymal Stem CellsRNASequence Analysis, RNATranscription FactorsUmbilical CordWharton JellyRNATranscription Factors

Identifiers

PMID35153292
PMCPMC8855628
OpenAlexW3214744379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.